Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Initiating Ph3 trials with remibrutinib in relapsing multiple sclerosis (3/3) Remibrutinib, potential best-in-class potency, selectivity and safety. May offer a more comprehensive and sustained BTK inhibition that allows for maximizing efficacy without compromising patient safety Autoantibodies Immune Complex B cell Receptor BTK inactive Fc Receptor Ksynthesis Kdegradation System-specific properties: Synthesis & degradation BTK BTK active BTK active B cell Myeloid Cell BTK inactive Drug-specific property: Irreversible binding BTK inhibitor remibrutinib Kirrev Cytokines Antigen presentation Inflammatory Mediators Proliferation Cytokines Organ Damage 18 Investor Relations | Q3 2021 Results Irreversible BTK binding ☐ 3 INNOVATION Covalently binds to the intracellular enzyme BTK in B cells and myeloid cells Potent BTK inhibition with brief and low systemic exposure which minimizes risk for AEs and drug-drug interactions CSU data Ph2a trial no dose-limiting side effects in Move directly into Ph3 in MS, with trials to start in Q4 2021 Novartis MS portfolio offers treatment options across the MS spectrum 1 NOVARTIS | Reimagining Medicine

View entire presentation